Skip to content


    DEA Class; Rx

    Common Brand Names; Stendra

    • Phosphodiesterase-5 Enzyme Inhibitors

    An oral phosphodiesterase type 5 (PDE5) inhibitor
    Used for erectile dysfunction (ED) and taken prior to anticipated sexual activity
    As with other PDE5 inhibitors, contraindicated for use with nitrates because the combination can cause a sudden drop in blood pressure

    Indicated for the treatment of erectile dysfunction (ED).


    Soluble guanylate cyclase (sGC) stimulators (eg, riociguat or vericiguat); concomitant use can cause hypotension

    • Headache (5.6%)
    • Flushing (3.5%)
    • Nasal congestion (2.1%)
    • Nasopharyngitis (3.4%)
    • Back pain (2.5%)
    • Upper respiratory infection (<2%)
    • Bronchitis (<2%)
    • Influenza (<2%)
    • Sinusitis (<2%)
    • Sinus congestion (<2%)
    • Hypertension (<2%)
    • Dyspepsia (<2%)
    • Nausea (<2%)
    • Constipation (<2%)
    • Rash (<2%)

    Potential for cardiovascular risk during sexual activity in patients with underlying cardiovascular conditions

    Monitor patients with left ventricular outflow obstruction (eg, aortic stenosis, idiopathic hypertrophic subaortic stenosis)

    Dose should not exceed 50 mg/24hr when taking avanafil concomitantly with moderate CYP3A4 inhibitors

    Initiate therapy at 50 mg/24hr if coadministered with antihypertensive medications like alpha-blockers

    Priapism may occur especially in patients with predisposed conditions (eg, sickle cell anemia, multiple myeloma, or leukemia)

    Discontinue therapy if sudden loss of vision in one or both eyes occur (could be a sign of non-arteritic anterior ischemic optic neuropathy)

    Safety and efficacy not established in patients with hereditary retinal disorders, including retinitis pigmentosa (use not recommended)

    Sudden hearing loss may occur; discontinue therapy if tinnitus symptoms occur

    Alcohol may increase risk for orthostatic hypotension; may increase heart rate and cause dizziness and headache

    Pregnancy Category: C

    Lactation: Safety and efficacy not established


    200 mg/day PO.


    200 mg/day PO.


    Safety and efficacy have not been established. 


    Safety and efficacy have not been established. 


    Safety and efficacy have not been established. 


    Safety and efficacy have not been established. 



    • 50mg
    • 100mg
    • 200mg